CODX
Co-Diagnostics, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Sell
-21/100
Last price
1.13
▲ 0.03 (2.73%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
1.12
Prev close
1.10
Day high
1.17
Day low
1.05
Volume
886.69K
Market cap
$8.03M
P/E (TTM)
—
52W range
0.91 – 46.50
Day trading desk
Gap from prior close
+1.82%
Prior close 1.10
VWAP
1.11
+2.03% from price
Relative volume
2.75×
Unusually busy
Session range
14.29%
1.05 – 1.20
Position in range
53%
Mid range
ATR (14D)
0.08
6.69% of price
Prior day high
1.21
PDH
Prior day low
1.08
PDL
Bid / ask spread
—
Quote not published
Session volume
867.42K
Avg 315.90K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+7.48%
+5.5%
1M
-0.86%
-2.0%
3M
-56.44%
-61.0%
6M
-19.01%
-37.2%
YTD
-77.32%
-91.6%
1Y
-90.02%
-106.4%
3Y
-96.38%
-178.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on CODX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
129.61K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| May 22, 26 | SERBIN RICHARD S Director |
STOCK | 1.70K | $0 | Direct |
| May 22, 26 | EGAN DWIGHT H. Chief Executive Officer |
STOCK | 4.58K | $0 | Direct |
| May 22, 26 | NELSON JAMES B Director |
STOCK | 1.70K | $0 | Direct |
| May 22, 26 | MURPHY EDWARD L. Director |
STOCK | 1.70K | $0 | Direct |
| May 22, 26 | DURENARD EUGENE A Director |
STOCK | 1.70K | $0 | Direct |
| May 22, 26 | BROWN BRIAN LEE Chief Financial Officer |
STOCK | 3.75K | $0 | Direct |
| May 22, 26 | ABBOTT RICHARD DAVID President |
STOCK | 1.89K | $0 | Direct |
| May 22, 26 | ABBOTT RICHARD DAVID President |
CONVERSION | 9.79K | $49.65K | Direct |
| May 22, 26 | EGAN DWIGHT H. Chief Executive Officer |
CONVERSION | 13.75K | $69.71K | Direct |
| May 22, 26 | NELSON JAMES B Director |
CONVERSION | 5.70K | $28.87K | Direct |
| May 22, 26 | MURPHY EDWARD L. Director |
CONVERSION | 5.70K | $28.87K | Direct |
| May 22, 26 | DURENARD EUGENE A Director |
CONVERSION | 5.70K | $28.87K | Direct |
| May 22, 26 | BROWN BRIAN LEE Chief Financial Officer |
CONVERSION | 11.25K | $57.04K | Direct |
| May 22, 26 | SERBIN RICHARD S Director |
CONVERSION | 5.70K | $28.87K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ABBOTT RICHARD DAVID |
President | 3.42K | Stock Award(Grant) |
BROWN BRIAN LEE |
Chief Financial Officer | 22.38K | Stock Award(Grant) |
DURENARD EUGENE A |
Director | 10.67K | Stock Award(Grant) |
EGAN DWIGHT H. |
Chief Executive Officer | 27.89K | Stock Award(Grant) |
MURPHY EDWARD L. |
Director | 11.08K | Stock Award(Grant) |
MURPHY TED |
Director | 224.17K | Conversion of Exercise of derivative security |
NELSON JAMES B |
Director | 10.67K | Stock Award(Grant) |
SERBIN RICHARD S |
Director | 10.75K | Stock Award(Grant) |
Fundamentals
Market cap$8.03M
Enterprise value$5.34M
Revenue (TTM)$721.39K
Gross profit$313.63K
EBITDA$-29.09M
Net income$-47.06M
EPS (TTM)$-26.14
Free cash flow$-17.49M
Total cash$3.65M
Total debt$1.80M
Book value / share$2.61
Shares outstanding6.98M
Float6.13M
Short % of float4.44%
Dividend yield0.00%
Beta (5Y)2.90
Valuation & profitability ratios
Trailing P/E—
Forward P/E-1.39
PEG ratio—
Price / sales—
Price / book0.44
EV / revenue7.40
EV / EBITDA-0.18
Gross margin43.48%
Operating margin-3732.47%
Profit margin0.00%
Return on equity-174.77%
Return on assets-59.63%
Debt / equity14.15
Current ratio1.81
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $622.49K | $3.92M | $6.81M | $34.22M | -84.1% |
| Operating revenue | $622.49K | $3.92M | $6.81M | $34.22M | -84.1% |
| Cost of revenue | $222.38K | $999.12K | $4.18M | $5.48M | -77.7% |
| Gross profit | $400.11K | $2.92M | $2.63M | $28.74M | -86.3% |
| Research & development | $19.14M | $20.98M | $22.96M | $17.44M | -8.8% |
| Selling, general & admin | $11.44M | $20.64M | $21.14M | $21.61M | -44.6% |
| Total operating expense | $31.68M | $43.00M | $45.33M | $40.33M | -26.3% |
| Operating income | -$31.28M | -$40.08M | -$42.71M | -$11.59M | +22.0% |
| Net interest income | $292.93K | $1.09M | $1.16M | $704.04K | -73.2% |
| Pre-tax income | -$48.51M | -$37.58M | -$38.11M | -$18.85M | -29.1% |
| Tax provision | -$1.62M | $57.37K | -$2.78M | -$4.61M | -2,916.9% |
| Net income | -$46.90M | -$37.64M | -$35.33M | -$14.24M | -24.6% |
| Net income to common | -$46.90M | -$37.64M | -$35.33M | -$14.24M | -24.6% |
| Basic EPS | -35.25 | -37.22 | -36.00 | -13.50 | +5.3% |
| Diluted EPS | -35.25 | -37.22 | -36.00 | -13.50 | +5.3% |
| EBIT | -$31.28M | -$40.08M | -$42.71M | -$11.59M | +22.0% |
| EBITDA | -$30.18M | -$38.70M | -$41.48M | -$10.31M | +22.0% |
| Basic shares | 1.33M | 1.01M | 978.22K | 1.05M | +31.5% |
| Diluted shares | 1.33M | 1.01M | 978.22K | 1.05M | +31.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $11.88M | $2.94M | $14.92M | $22.97M | +304.7% |
| Cash & short-term investments | $11.88M | $29.75M | $58.55M | $81.26M | -60.0% |
| Accounts receivable | $190.38K | $132.57K | $303.93K | $3.45M | +43.6% |
| Inventory | $992.40K | $1.07M | $1.66M | $5.31M | -7.5% |
| Total current assets | $13.69M | $32.29M | $62.14M | $92.73M | -57.6% |
| Property, plant & equipment | $3.48M | $4.88M | $6.00M | $2.91M | -28.6% |
| Goodwill & intangibles | $7.22M | $26.10M | $26.40M | $26.77M | -72.3% |
| Total assets | $24.74M | $63.56M | $95.32M | $123.09M | -61.1% |
| Total current liabilities | $3.54M | $7.32M | $5.75M | $3.87M | -51.6% |
| Total debt | $1.24M | $2.15M | $2.99M | $347.92K | -42.5% |
| Total liabilities | $4.11M | $9.69M | $9.31M | $8.57M | -57.5% |
| Retained earnings | -$80.37M | -$33.48M | $4.60M | $39.93M | -140.1% |
| Shareholder equity | $20.63M | $53.88M | $86.01M | $114.52M | -61.7% |
| Working capital | $10.15M | $24.98M | $56.39M | $88.86M | -59.3% |
| Net tangible assets | $13.41M | $27.77M | $59.61M | $87.75M | -51.7% |
| Shares issued | 2.26M | 1.26M | 1.20M | 1.16M | +78.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$46.90M | -$37.64M | -$35.33M | -$14.24M | — | -24.6% |
| Depreciation & amortisation | $1.11M | $1.38M | $1.23M | $1.28M | — | -19.6% |
| Stock-based compensation | $2.25M | $5.43M | $8.34M | $7.54M | — | -58.6% |
| Change in working capital | -$3.17M | $2.75M | $5.64M | $6.19M | — | -215.0% |
| Operating cash flow | -$29.14M | -$29.16M | -$22.08M | $6.57M | — | +0.1% |
| Capital expenditure | -$700.05K | -$748.35K | -$1.37M | -$1.43M | — | +6.5% |
| Investing cash flow | $26.27M | $17.07M | $15.39M | -$58.17M | — | +53.9% |
| Share buybacks | — | $0 | -$1.36M | -$14.21M | $0 | — |
| Financing cash flow | $11.81M | $103.91K | -$1.36M | -$14.03M | — | +11,266.7% |
| Free cash flow | -$29.84M | -$29.90M | -$23.45M | $5.14M | — | +0.2% |
| End cash position | $11.88M | $2.94M | $14.92M | $22.97M | — | +304.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $166.13K | $145.95K | $263.92K | $145.38K | $162.91K | — | +13.8% |
| Operating revenue | $166.13K | $145.95K | $263.92K | $145.38K | $162.91K | — | +13.8% |
| Cost of revenue | $45.30K | $193.77K | $142.40K | $26.29K | $32.11K | — | -76.6% |
| Gross profit | $120.83K | -$47.81K | $121.53K | $119.09K | $130.80K | — | +352.7% |
| Research & development | $4.15M | $5.93M | $5.10M | $4.48M | $4.69M | — | -30.0% |
| Selling, general & admin | $1.97M | $2.97M | $2.41M | $2.38M | $3.21M | — | -33.8% |
| Total operating expense | $6.32M | $9.16M | $7.78M | $7.13M | $8.19M | — | -31.0% |
| Operating income | -$6.20M | -$9.21M | -$7.66M | -$7.01M | -$8.06M | — | +32.7% |
| Net interest income | $17.49K | $6.97K | $253.98K | $13.19K | $12.16K | — | +150.8% |
| Pre-tax income | -$6.26M | -$9.14M | -$26.22M | -$7.05M | -$7.72M | — | +31.5% |
| Tax provision | $19.17K | $520 | -$473.72K | -$1.17M | $12.33K | — | +3,586.2% |
| Net income | -$6.28M | -$9.14M | -$25.75M | -$5.89M | -$7.73M | — | +31.2% |
| Net income to common | -$6.28M | -$9.14M | -$25.75M | -$5.89M | -$7.73M | — | +31.2% |
| Basic EPS | -1.46 | -4.06 | — | -4.80 | -7.00 | -7.05 | +64.0% |
| Diluted EPS | -1.46 | -4.06 | — | -4.80 | -7.00 | -7.05 | +64.0% |
| EBIT | -$6.20M | -$9.21M | -$7.66M | -$7.01M | -$8.06M | — | +32.7% |
| EBITDA | -$6.00M | -$8.95M | -$7.39M | -$6.75M | -$7.77M | — | +33.0% |
| Basic shares | 4.31M | 2.25M | — | 1.26M | 1.10M | 1.07M | +91.3% |
| Diluted shares | 4.31M | 2.25M | — | 1.26M | 1.10M | 1.07M | +91.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.65M | $8.23M | $11.88M | $11.44M | $11.12M | -55.7% |
| Cash & short-term investments | $3.65M | $8.23M | $11.88M | $11.44M | $13.36M | -55.7% |
| Accounts receivable | $52.06K | $82.34K | $190.38K | $55.91K | $210.97K | -36.8% |
| Inventory | $841.67K | $846.12K | $992.40K | $1.09M | $1.08M | -0.5% |
| Total current assets | $5.19M | $9.78M | $13.69M | $14.05M | $15.31M | -46.9% |
| Property, plant & equipment | $3.74M | $4.16M | $3.48M | $3.92M | $4.34M | -10.0% |
| Goodwill & intangibles | $7.22M | $7.22M | $7.22M | $26.10M | $26.10M | 0.0% |
| Total assets | $16.59M | $21.50M | $24.74M | $44.74M | $46.47M | -22.8% |
| Total current liabilities | $2.86M | $4.28M | $3.54M | $3.69M | $3.71M | -33.2% |
| Total debt | $1.80M | $2.03M | $1.24M | $1.47M | $1.70M | -11.4% |
| Total liabilities | $3.88M | $5.46M | $4.11M | $4.91M | $5.33M | -28.9% |
| Retained earnings | -$95.80M | -$89.51M | -$80.37M | -$54.19M | -$48.30M | -7.0% |
| Shareholder equity | $12.71M | $16.04M | $20.63M | $39.83M | $41.14M | -20.8% |
| Working capital | $2.33M | $5.50M | $10.15M | $10.36M | $11.60M | -57.6% |
| Net tangible assets | $5.49M | $8.82M | $13.41M | $13.73M | $15.04M | -37.7% |
| Shares issued | 4.88M | 3.76M | 2.26M | 1.77M | 1.37M | +29.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$6.28M | -$9.14M | -$25.75M | -$5.89M | -$7.73M | +31.2% |
| Depreciation & amortisation | $201.84K | $255.44K | $267.57K | $267.38K | $291.41K | -21.0% |
| Stock-based compensation | $213.75K | $219.11K | $291.98K | $500.58K | $580.26K | -2.4% |
| Change in working capital | -$1.33M | $906.19K | $92.05K | -$782.70K | -$1.16M | -247.2% |
| Operating cash flow | -$7.15M | -$7.85M | -$6.20M | -$5.90M | -$8.29M | +8.8% |
| Capital expenditure | -$18.28K | -$142.02K | -$131.97K | -$75.11K | -$401.06K | +87.1% |
| Investing cash flow | -$168.28K | -$142.02K | -$329.42K | $2.17M | $17.07M | -18.5% |
| Financing cash flow | $2.74M | $4.33M | $6.97M | $4.06M | $429.00K | -36.8% |
| Free cash flow | -$7.17M | -$7.99M | -$6.33M | -$5.98M | -$8.69M | +10.2% |
| End cash position | $3.65M | $8.23M | $11.88M | $11.44M | $11.12M | -55.7% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -3.00 | -1.45 | +51.6% |
| Mar 2026 | -3.75 | -4.09 | -9.1% |
| Dec 2025 | -3.60 | -4.44 | -23.3% |
| Sep 2025 | -5.70 | -4.66 | +18.2% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -1.25 | 1 | $169.00K | +16.3% |
| Next quarter | -0.27 | 1 | $173.00K | -34.4% |
| Current year | -3.10 | 1 | $654.00K | +5.1% |
| Next year | -0.83 | 1 | $17.31M | +2,546.5% |
Analyst targets & ownership
Mean target$4.00
High target$4.00
Low target$4.00
Implied upside253.98%
Analyst count1
ConsensusBUY
Strong buy / Buy1 / 0
Hold0
Sell / Strong sell0 / 0
Held by insiders2.07%
Held by institutions10.53%
Institutions holding27
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.10
+2.73% from price
SMA 20
1.08
+6.94% from price
SMA 50
1.23
-6.48% from price
SMA 100
2.49
-54.68% from price
SMA 200
2.68
-57.15% from price
EMA 12
1.09
+3.20% from price
EMA 26
1.15
-1.84% from price
EMA 50
1.41
-19.93% from price
RSI (14)
49.1
Neutral
MACD (12,26,9)
-0.06
Hist 0.03
ATR (14)
0.08
6.57% of price
Realised vol 30D
72.4%
Annualised
Bollinger upper
1.20
20, 2σ
Bollinger lower
0.95
20, 2σ
50 / 200 cross
Death
1.23 vs 2.68
Trend bias
Below 200
-57.15%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
3.12
More volatile than market
Correlation to SPY
0.12
Largely independent
Realised vol 30D
72.4%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-97.5%
Peak to trough
Max drawdown 5Y
-99.7%
Peak to trough
ATR 14
0.08
6.57% of price
Beta (reported)
2.90
5Y monthly, from filing
Short interest
Shares short
304.97K
Prior 362.63K
Change vs prior
-15.9%
Shorts covering
% of float
4.44%
Normal
% of shares out
4.37%
Against total outstanding
Days to cover
1.2
Liquid
Float
6.13M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 26, 25 | Maxim Group | INITIATED | — | Buy |
| Nov 24, 25 | HC Wainwright & Co. | MAINTAINED | Neutral | Neutral |
| Oct 28, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Oct 16, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Sep 19, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Sep 17, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Aug 15, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Apr 28, 25 | D. Boral Capital | INITIATED | — | Buy |
| Mar 28, 25 | HC Wainwright & Co. | MAINTAINED | Neutral | Neutral |
| Nov 11, 24 | HC Wainwright & Co. | MAINTAINED | Neutral | Neutral |
| Aug 12, 24 | HC Wainwright & Co. | MAINTAINED | Neutral | Neutral |
| Jun 17, 24 | HC Wainwright & Co. | MAINTAINED | Neutral | Neutral |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:30
Split dateJan 2, 2026
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-10-05
Corporate Changes & Voting Matters
8-K · 2026-09-25
Proxy Statements
PRE 14A · 2026-09-21
Corporate Changes & Voting Matters
8-K · 2026-09-16
Corporate Changes & Voting Matters
8-K · 2026-09-15
Corporate Changes & Voting Matters
8-K · 2026-09-04
Offering Registrations
S-3 · 2026-08-24
Periodic Financial Reports
10-Q · 2026-08-13
Headlines
Co-Diagnostics to Showcase Co-Dx PCR Platform* and MTB Test at WHX Labs Johannesburg, Highlight Ebola Assay Development
PR Newswire · 19h ago
Co-Diagnostics to Participate in Global Health Events During UN General Assembly Week
PR Newswire · 14d ago
Co-Diagnostics to Participate in Global Health Roundtable on Ebola and Outbreak Innovation
PR Newswire · 16d ago
Co-Diagnostics to Participate in Joint WHO/Unitaid/UNAIDS Annual Consultation Meeting on September 17-18, 2026
PR Newswire · 20d ago
Co-Diagnostics and ReadyGo Collaborate to Evaluate Blood-Based Molecular Testing at the Point of Need, Starting with Ebola
PR Newswire · 21d ago
Co-Diagnostics to Hold Press Conference
PR Newswire · 21d ago
Co-Diagnostics Launches Integrated Cloud and Mobile Infrastructure in India
PR Newswire · 34d ago
Co-Diagnostics Expands Vector Smart® Customer Reach with First International Installation in USAF Base
PR Newswire · 36d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.